| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Lamiae Zarraa, Imane Assarrar, Oumaima Magouri, Zahi Ismaili, Siham Rouf, Hanane Latrec. Biliary Tract Disorders and Associated Acute Complications in Patients With Acromegaly: A Single-Center Study. Journal of clinical medicine research. vol 16. issue 4. 2024-05-08. PMID:38715563. |
these complications may be secondary either to acromegaly or to somatostatin analogs (sas). |
2024-05-08 |
2024-05-27 |
Not clear |
| Khaled Ahmed Baagar, Amna Sadiq, Adeel Ahmad Khan, Zeinab Dabbous, Zaina Rohan. Successful medical management of a pituitary macroadenoma with features of resistant acromegaly and hyperprolactinemia using pasireotide. Qatar medical journal. vol 2024. issue 1. 2024-04-26. PMID:38654814. |
the somatostatin analog, pasireotide, is used for the treatment of acromegaly after the failure of surgery and/or first-line medical treatment. |
2024-04-26 |
2024-04-28 |
Not clear |
| Ulla Feldt-Rasmussen, Marek Bolanowski, Shao-Ling Zhang, Yerong Yu, Przemysław Witek, Pramila Kalra, Noppadol Kietsiriroje, Andrea Piacentini, Alberto M Pedroncelli, Susan L Samso. Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment: Frontiers in endocrinology. vol 15. 2024-04-05. PMID:38577574. |
predictive factors and the management of hyperglycemia in patients with acromegaly and cushing's disease receiving pasireotide treatment: pasireotide, a somatostatin receptor ligand, is approved for treating acromegaly and cushing's disease (cd). |
2024-04-05 |
2024-04-07 |
Not clear |
| Mónica Marazuela, Rebeca Martínez-Hernandez, Montserrat Marques-Pamies, Betina Biagetti, Marta Araujo-Castro, Manel Puig-Doming. Predictors of biochemical response to somatostatin receptor ligands in acromegaly. Best practice & research. Clinical endocrinology & metabolism. 2024-04-04. PMID:38575404. |
predictors of biochemical response to somatostatin receptor ligands in acromegaly. |
2024-04-04 |
2024-04-07 |
Not clear |
| Mónica Marazuela, Rebeca Martínez-Hernandez, Montserrat Marques-Pamies, Betina Biagetti, Marta Araujo-Castro, Manel Puig-Doming. Predictors of biochemical response to somatostatin receptor ligands in acromegaly. Best practice & research. Clinical endocrinology & metabolism. 2024-04-04. PMID:38575404. |
although predictors of response to first-generation somatostatin receptor ligands (fg-srls), and to a lesser extent to pasireotide, have been studied in acromegaly for many years, their use is still not recommended in clinical guidelines. |
2024-04-04 |
2024-04-07 |
Not clear |
| R Pirchio, R S Auriemma, A Vergura, R Pivonello, A Cola. Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center. Journal of endocrinological investigation. 2024-03-27. PMID:38532073. |
pasireotide is a novel therapeutic option for patients with acromegaly resistant to first-generation somatostatin receptor ligands. |
2024-03-27 |
2024-03-29 |
Not clear |
| Dermot O'Toole, Pamela L Kunz, Susan M Webb, Grace Goldstein, Sheila Khawaja, Mark McDonnell, Sandra Boiziau, Delphine Gueguen, Aude Houchard, Antonio Ribeiro-Oliveira, Ally Prebtan. Correction to: PRESTO 2: An International Survey to Evaluate Patients' Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly. Advances in therapy. 2024-03-14. PMID:38480663. |
correction to: presto 2: an international survey to evaluate patients' injection experiences with the latest devices/formulations of long-acting somatostatin analog therapies for neuroendocrine tumors or acromegaly. |
2024-03-14 |
2024-03-16 |
Not clear |
| Ilan Remba-Shapiro, Lisa B Nachtigal. Treatment of acromegaly with oral octreotide. Best practice & research. Clinical endocrinology & metabolism. 2024-03-05. PMID:38443224. |
somatostatin receptor ligands (srl) are the mainstay of medical therapy for patients with acromegaly who fail to achieve biochemical control post-operatively or are not eligible for surgical treatment. |
2024-03-05 |
2024-03-08 |
Not clear |
| Mei Luo, Jiangfan Yu, Rui Tan. Immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in Acromegaly. Journal of neuro-oncology. 2024-03-05. PMID:38441839. |
immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in acromegaly. |
2024-03-05 |
2024-03-07 |
Not clear |
| Mei Luo, Jiangfan Yu, Rui Tan. Immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in Acromegaly. Journal of neuro-oncology. 2024-03-05. PMID:38441839. |
predicting resistance to first-generation somatostatin receptor ligands (fg-srl) in acromegaly patients remains an ongong challenge. |
2024-03-05 |
2024-03-07 |
Not clear |
| E O Mamedova, E G Przhiyalkovskaya, S A Buryakina, E V Bondarenko, A M Lapshina, M Yu Pikunov, Zh E Belaya, G A Melnichenk. [Ectopic acromegaly due to bronchial neuroendocrine tumors: the first description in Russia of three clinical cases]. Problemy endokrinologii. vol 70. issue 1. 2024-03-04. PMID:38433543. |
treatment of ectopic acromegaly consists of surgical removal of the source of ghrh hyperproduction and in cases where surgery is not an option, somatostatin analogues, pegvisomant, chemotherapy, immunotherapy or radiation therapy are used.in this article three cases of ectopic acromegaly due to ghrh-producing lung nets are presented, each of them being notable for a number of features. |
2024-03-04 |
2024-03-06 |
Not clear |
| Sylvère Störmann, Sebastian M Meyhöfer, Jan B Groener, Johanna Faust, Katharina Schilbach, Jochen Seufert, Bruno Vergè. Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts' consensus statement. Frontiers in endocrinology. vol 15. 2024-02-26. PMID:38405148. |
pasireotide is a somatostatin analogue for the treatment of acromegaly, a chronic condition caused by excess growth hormone. |
2024-02-26 |
2024-02-28 |
Not clear |
| Salman Zahoor Bhat, Roberto Salvator. Current role of pasireotide in the treatment of acromegaly. Best practice & research. Clinical endocrinology & metabolism. 2024-01-30. PMID:38290866. |
"first-generation" somatostatin receptor agonists (sstras) octreotide and lanreotide are the most commonly used first-line pharmacological therapy for patients with acromegaly. |
2024-01-30 |
2024-02-02 |
Not clear |
| C Urbani, F Dassie, B Zampetti, R Mioni, P Maffei, R Cozzi, F Bogazz. Real-life data of Pasireotide LAR in acromegaly: a long-term follow-up. Journal of endocrinological investigation. 2024-01-20. PMID:38244140. |
pasireotide lar (pas-lar) was released in italy in 2017 to treat acromegaly patients resistant to srls (somatostatin receptors ligands). |
2024-01-20 |
2024-01-23 |
Not clear |
| Sandrine A Urwyler, Irene Samperi, Kirstie Lithgow, Akash Mavilakandy, Mike Matheou, Karin Bradley, Aparna Pal, Narendra L Reddy, John Ay, Niki Karavitak. Efficacy of cabergoline in non-irradiated patients with acromegaly: a multi-centre cohort study. European journal of endocrinology. 2024-01-17. PMID:38231133. |
elucidate the efficacy (as per current biochemical criteria) of cabergoline monotherapy or as addition to long-acting somatostatin receptor ligand (srl) in patients with acromegaly and no previous pituitary radiotherapy. |
2024-01-17 |
2024-01-19 |
Not clear |
| Zihan Wang, Zhuowei Lei, Quanji Wang, Qian Jiang, Zhuo Zhang, Xiaojin Liu, Biao Xing, Sihan Li, Xiang Guo, Yanchao Liu, Xingbo Li, Yiwei Qi, Kai Shu, Huaqiu Zhang, Yimin Huang, Ting Le. Connexin 36 Mediated Intercellular Endoplasmic Reticulum Stress Transmission Induces SSTA Resistance in Growth Hormone Pituitary Adenoma. International journal of biological sciences. vol 20. issue 2. 2024-01-03. PMID:38169563. |
somatostatin analogues (ssta) are first-line pharmacological treatment choice for acromegaly, which received satisfying tumor shrinkage and normalization of growth hormone. |
2024-01-03 |
2024-01-06 |
Not clear |
| Mirela-Diana Ilie, Gérald Raverot, Aude Brac de la Perrièr. Pasireotide - potential treatment option for McCune Albright-associated acromegaly. European journal of endocrinology. 2023-12-21. PMID:38128124. |
only 30% of patients with mccune albright syndrome (mas)-associated acromegaly achieve biochemical control under first-generation somatostatin receptor ligands (fg-srls), while pegvisomant fails to normalize igf-i in >20% of cases. |
2023-12-21 |
2023-12-24 |
Not clear |
| Daniela Regazzo, Serena Avallone, Cliona P MacSweeney, Eugenia Sergeev, David Howe, Alex Godwood, Kirstie A Bennett, Alastair J H Brown, Matt Barnes, Gianluca Occhi, Mattia Barbot, Diego Faggian, Maria Pia Tropeano, Marco Losa, Giovanni Lasio, Carla Scaroni, Francesca Pecori Girald. A Novel Somatostatin Receptor Ligand for Human ACTH- and GH-secreting Pituitary Adenomas. European journal of endocrinology. 2023-12-20. PMID:38123488. |
these findings suggest a potential new avenue for somatostatin ligands in the treatment of cushing's disease and acromegaly. |
2023-12-20 |
2023-12-23 |
human |
| Montserrat Marques-Pamies, Joan Gil, Mireia Jordà, Manel Puig-Doming. Predictors of Response to Treatment with First-Generation Somatostatin Receptor Ligands in Patients with Acromegaly. Archives of medical research. 2023-12-02. PMID:38042683. |
predictors of response to treatment with first-generation somatostatin receptor ligands in patients with acromegaly. |
2023-12-02 |
2023-12-10 |
Not clear |
| Montserrat Marques-Pamies, Joan Gil, Mireia Jordà, Manel Puig-Doming. Predictors of Response to Treatment with First-Generation Somatostatin Receptor Ligands in Patients with Acromegaly. Archives of medical research. 2023-12-02. PMID:38042683. |
predictors of first-generation somatostatin receptor ligands (fgsrls) response in acromegaly have been studied for over 30 years, but they are still not recommended in clinical guidelines. |
2023-12-02 |
2023-12-10 |
Not clear |